What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- Tested for
- Neoplasms
- Main trialPhase 2
- “This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.”In the company’s words, NCT03967223 on ClinicalTrials.gov
Other drugs for Neoplasms
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 1 Mar 2024 | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | |
| Phase 2Completed | 1 Nov 2021 | Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma | |
| Phase 2Completed | 12 Oct 2022 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma | |
| Phase 2Completed | 1 Mar 2024 | Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |
| Phase 1Terminated | 13 Jul 2020 | Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | |
| Phase 1Completed | 10 Aug 2020 | Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 1Authorised | not given | Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026